1. Gilead Sciences EVP Jim Meyers said pharmacy benefit managers are the ones keeping drug prices high, saying that if Gilead lowered prices of certain drugs the PBMs would “rip up our contract.” (Bloomberg)
2. Google is using deep learning to detect signs of breast cancer. The tech giant partnered with a Dutch university to analyze thousands of cancer cell slides. (CNN)
3. Sanofi and Regeneron’s experimental eczema drug Dupixent was more effective when used with topical corticosteroids, compared to using topical corticosteroids alone, according to a one-year study. The drug received priority review in September. (Reuters)
4. The FDA approved Allergan and Serenity Pharmaceuticals’ nasal spray Noctiva, the first drug to reduce frequent nighttime urination. The drug has a black-box warning. (AP)
5. OncoCyte, a diagnostics company, said a 300-patient study of its blood test to detect lung cancer confirmed a previous trial’s accuracy. The drugmaker plans to launch the test later this year. (Reuters)
